



### 2201 SHANNON PLACE, SE 2<sup>ND</sup> FLOOR WASHINGTON, DC 20020

December 5, 2024

### 9:32 AM - 10:05 AM

# OPEN SESSION MINUTES (WEBEX MEETING)

#### **Board of Pharmacy Mission Statement:**

"To protect and improve the public health through the efficient and effective regulation of the practice of Pharmacy and Pharmaceutical Detailing; through the licensure of Pharmacists, Pharmaceutical Detailers, Pharmacy Interns, and Pharmacy Technicians."

### CALL TO ORDER: 9:32 AM

### PRESIDING: MR. ALAN FRIEDMAN, R.PH, VICE CHAIRPERSON

### BOARD MEMBERSHIP/ATTENDANCE:

	•	
BOARD MEMBERS:		
	MR. ALAN FRIEDMAN, R.PH, VICE CHAIRPERSON	Present
	DR. BENJAMIN MILES, PHARM.D. R.PH	Present
	DR. ASHLEE BOW, PHARM.D. R.PH	Present
	DR. ALLISON HILL, PHARM.D. R.PH	Absent
	MR. RODRICK MCGILL, ESQ. CONSUMER MEMBER	Present
STAFF:	DR. JUSTIN ORTIQUE, PHARM.D., R.PH, EXECUTIVE DIRECTOR	Present
	DR. REGINAL BELLAMY, PHARM.D., R.PH, SUPERVISORY PHARMACIST	PRESENT
	KARIN BARRON, HEALTH LICENSING SPECIALIST	PRESENT
	LUANNE GREENAWAY, PROGRAM SPECIALIST	
		PRESENT
	COUNTEE GILLIAM, BOARD INVESTIGATOR	Present
LEGAL STAFF:	CARLA WILLIAMS, SENIOR ASSISTANT GENERAL COUNSEL	Present
VISITORS:	Amos Chery, Medstar Washington Hospital Center	
	JOAN LELMA, BOARD OF ETHICS AND GOVERNMENT ACCOUNTABILITY	
	JOANNE DIAL, KAISER PERMANENTE	
	KARLA EVANS, MEDSTAR WASHINGTON HOSPITAL CENTER	
	GAIL ELLIOTT, KAISER PERMANENTE	
	SCOTT TOMERLIN, WALGREENS PHARMACY	
	SUSAN DELMONICO, GENOA HEALTHCARE	
	NICOLE DANIELS	
	JESSICA PARKER WOO	

## Open Session Agenda Quorum: Yes

Introduction:		
1205-0-01	Approval of the Open Session Meeting Minutes for:	
	October 3, 2024, Open Session Meeting Minutes	
	<b>Motion</b> : Board Member, Dr. Ashlee Bow moved that the Board approves the October 3, 2024, open session meeting minutes.	
	Seconded by: Board Member, Dr. Benjamin Miles	
	Dr. Benjamin Miles: Votes in favor of the motion. Dr. Ashlee Bow: Votes in favor of the motion. Dr. Allison Hill: Absent Mr. Roderick McGill: Votes in favor of the motion.	
	Abstentions: None.	
	Motion carried.	
	• November 7, 2024, Open Session Meeting Minutes	
	<b>Motion</b> : Board Member, Mr. Roderick McGill moved that the Board approves the November 7, 2024, open session meeting minutes.	
	Seconded by: Board Member, Dr. Ashlee Bow.	
	Dr. Benjamin Miles: Votes in favor of the motion. Dr. Ashlee Bow: Votes in favor of the motion. Dr. Allison Hill: Absent. Mr. Roderick McGill: Votes in favor of the motion.	
	Abstentions: None.	
	Motion carried.	
<u>Consent Agenda</u>	None	
<u>Vice Chairperson</u> <u>Report</u>	None	Mr. Alan Friedman
<u>Office of</u> Government	Board Confirmation Roundtable:	Dr. Justin Ortique

<u>Relations (OGR)</u> <u>Report Updates</u>	<ul> <li>The Committee on Health held a roundtable 2024 to discuss the nominees for the Boards Nursing, Medicine, Professional Counseling, Therapy.</li> <li>An additional meeting on November 18, 2024 nominees of the Committee on Health to awa the DC Council. All nominees were voted on hof the Whole, and passed, during the Novem legislative meeting.</li> <li>The nominee for the Board of Pharmacy is Dr DC Council's Winter Recess will begin on Decand end on January 2, 2025, ending Council Preturn from recess, DC Council will begin Period</li> </ul>	of Pharmacy, and Massage 4 advanced the ait a final vote by by the Committee ber 26, 2024 7. Jamila Jorden. ember 23, 2024, Period 25. On its	
Executive Director Report	Statistical Report on Pharmacy Professionals in the Columbia	e District of	Dr. Justin Ortique
	PHARMACEUTICAL DETAILERS	739	
	PHARMACISTS	2,330	
	PHARMACY INTERNS	339	
	PHARMACY TECHNICIANS	1,349	
	PHARMACY TECHNICIAN TRAINEES	170	
	PHARMACISTS WITH VAC AUTHORITY	884	
	PHARMACY TECHNICIAN TRAINING PROGRAMS	14	
	<ul> <li>Prescription Drug Monitoring Program Updates</li> <li>All pharmacists are reminded to register for the Drug Monitoring Program (PDMP) within ninellicensure in the District of Columbia at <a href="https://districtofcolumbia.pmpaware.net/log">https://districtofcolumbia.pmpaware.net/log</a></li> <li>As a reminder, new licensees will receive notic registration for the program every thirty (30) licensure. Licensees who fail to comply are suffined.</li> <li>The next PDMP Advisory Committee Meeting Tuesday, December 10, 2024, from 10:00 AM</li> <li>DCRx (DC Center for Rational Prescribing)</li> <li>The Board of Pharmacy's vendor, Innovation honored its contract with the Board by releas modules for continuing education credits for</li> </ul>	ty (90) days of <u>in</u> . fications regarding days after ubject to being is scheduled for I -11:30 AM. <i>Horizons</i> , has sing all four (4)	

	A DCRx Annual Learner Survey was recently transmitted via	
	email, and via PDMP announcements today.	
	• Thank you to all who completed surveys; they will be used in	
	planning for the upcoming year.	
	Pharmacists and Pharmacy Technicians: Upcoming Renewal	
	<ul> <li>Renewals are set to begin on January 2, 2025, as an email announcing the opening of the renewal period will be disseminated throughout the District's pharmacy community in the upcoming weeks.</li> <li>The email will include information on the Board of Pharmacy's change in the licensure renewal process wherein licensure renewal will be due by the end of the licensee's birth month in the next odd year for licensees born in an odd year, and the next even year for licensees born in an even year.</li> <li>All licensure renewal applications will be accessible at <a href="https://doh.force.com/dchealthrenewals/s/portal-page">https://doh.force.com/dchealthrenewals/s/portal-page</a>.</li> </ul>	
<u>Senior Assistant</u> <u>General Counsel</u> <u>Report</u>		
1205-0-02	Notice of Proposed Rulemaking (re the Working Conditions	Ms. Carla
	Regulations for Pharmacists)	Williams
	<ul> <li>(a) Chapter 19, Pharmacies, of Subtitle B, Public Health and Medicine, Title 22</li> </ul>	
	The Pharmaceutical Control Division has published proposed	
	rulemaking – concerning Chapter 19, Pharmacies, of Subtitle B,	
	Public Health and Medicine, Title 22 – for comment.	
	• This rulemaking, which was published in the DC Register on	
	November 22, 2024, entered the thirty (30) day comment	
	period, which will end on December 24, 2024.	
	• All stakeholders, as well as Line Pharmacists (who will be most	
	affected by this rulemaking) are encouraged to submit	
	comments.	
<u>Subcommittee</u>		
<u>Reports</u>		
1205-0-03	Legislative and Regulatory Subcommittee Report	Mr. Alan
		Friedman
	The Subcommittee elected to recess during November –	
	December, 2024.	
	The Subcommittee has made significant progress in identifying	
	the areas within the HORA changes wherein pharmacists and	
	pharmacy technicians – and where applicable, pharmaceutical	
	detailers – can move forward with the legislative changes.	
	<ul> <li>The Subcommittee has also identified areas within the HORA</li> </ul>	

	<ul> <li>changes wherein the Board of Pharmacy needs to provide further guidance through the regulatory process [for some of the HORA changes].</li> <li>The Subcommittee will continue its work in January, 2025 on the Prep and PEP, emergency field regulations, and shared services.</li> <li>The Subcommittee will also make recommendations to the Pharmaceutical Control Division.</li> <li>The next <i>Open Session Legislative and Regulatory Subcommittee</i> meeting is tentatively scheduled for January 29, 2025 from 2:00 PM – 3:00 PM.</li> </ul>	
1205-O-04	<ul> <li>Communications Subcommittee Report</li> <li>The Communications Subcommittee is currently working on its next publication of the newsletter, which is expected to be released in January, 2025.</li> <li>All are encouraged to register to receive the newsletter at nabp.pharmacy.</li> </ul>	Dr. Ashlee Bow
<u>Pharmacy</u> <u>Technician Task</u> <u>Force</u>	• The Pharmacy Technician Task Force anticipates its first meeting at the beginning of the year.	
NABP E- Newsletters	<ul> <li>November 13, 2024</li> <li>NABP Collaborates to Launch Pulse by NABP Pilot in South Africa</li> <li>The 2024 National Pharmacy Workforce Study Is Live!</li> <li>FDA's OA REMS Program to Allow Pharmacies to Request Mail-Back Envelopes for Opioid Analgesics</li> <li>ISMP Publishes Guidance for Imported Fluid Products</li> <li>LAPPA Publishes Model Language Related to Pharmacist Management of Overdose Reversal Medications</li> <li>US Antibiotic Awareness Week Is November 18-24</li> <li>November 20, 2024</li> <li>NABP Blog: Transformative Technologies Present Opportunities for Pharmacy Practice and Regulation.</li> <li>NABP's Webinars Offer CPE Credit for Pharmacy Professionals.</li> <li>FDA Proposes Removing Oral Phenylephrine as Active Ingredient from Nasal Congestion Products</li> </ul>	Mr. Alan Friedman

	October Drug Take Back Day Removes 630,000 Pounds of Unneeded Medications from Homes Across the Country
	CDC Advises Pneumococcal Vaccine for Individuals 50 Years and Older
	NABP's Director of Innovation Shares DSCSA Insights at Seminar
	NABP Accepting Nominations for 2025 Leadership Awards
	Note to the Public: To receive weekly updates from NABP, please sign up by using the following link: https://nabp.pharmacy/newsroom/news/.
Comments from the Public	Karla Evans asks the Board to explain the process of rulemaking beyond the comment period.
	Board Vice Chairperson, Mr. Friedman responds as follows:
	• Rulemaking is published in the DC Register and open for public comment for thirty (30) days, after which it returns to the Board for comment review. (Comments should be submitted in writing, by December 24, 2024. The instructions on submitting comments should be in the Register).
	• The Board will review all comments and if the Board chooses to leave the regulations as they are currently proposed, then the Board would approve the regulations at the next available Open Session meeting and publish them as final.
	<ul> <li>If upon comment review the Board decides that substantial changes are to be made, the drafted regulations will be modified, republished in the Register and will enter a second comment period.</li> </ul>
	• The proposed regulations would complete the aforementioned process until no revisions are made. Then, the regulations would be published as final.
	Board Counsel, Ms. Carla Williams adds the following:
	Please observe that the current proposed regulations are those of the Pharmaceutical Control Division. The Board shares these proposed regulations at Open Session meetings as this is the best opportunity to reach all stakeholders and members of the public.
	Therefore, the process would be such that after the comment period closes, the comments will be reviewed by the Pharmaceutical Control Division and if changes are made to the proposed regulations, they are republished.
	If there are substantive issues where the pharmaceutical control division requests the Board's opinion, then the Board may advise the

	Motion Carried.
	Abstentions: None.
	Mr. Roderick McGill: Votes in favor of the motion.
	Dr. Allison Hill: Absent.
	Dr. Ashlee Bow: Votes in favor of the motion.
	Dr. Benjamin Miles: Votes in favor of the motion.
	Roll Call Vote:
	Seconded by: Board Member, Mr. Roderick McGill.
	to § 2-575(b)(4); and to plan, discuss, or hear reports concerning ongoing or planned investigations pursuant to § 2-575(b)(14)." ROLL CALL VOTE
	attorney-client privilege, or to approve settlement agreements pursuant
	for the following purposes: to discuss disciplinary matters pursuant to § 2-575(b)(9); to seek the advice of counsel to the board, to preserve the
	Session portion of the meeting pursuant to D.C. Official Code § 2-575(b)
<u> Open Session</u>	"Mister Vice Board Chair, I move that the Board close the Open Public session portion of the meeting and move into the Closed Executive
Adjourn the	
Motion to	Board member, Dr. Benjamin Miles, moves as follows:
	changes to proposed legislation lies with DC Health.
	pharmaceutical control division. Ultimately, the decision to make

This concludes the Public Open Session of the meeting. The Board will now move into the Closed Executive Session portion of the meeting pursuant to D.C. Official Code § 2-575(b) for the reasons set forth in the motion.

Open Session Meeting Adjourned at <u>10:05</u> AM.

This meeting is governed by the Open Meetings Act. Please address any questions or complaints arising under this meeting to the Office of Open Government at opengovoffice@dc.gov.